38% Lower Worsening-Heart-Failure or CV-Death Risk With Tirzepatide
SUMMIT tested tirzepatide in adults with obesity-related HFpEF, following participants for a median of two years. The headline result is a relative reduction in a composite cardiovascular-death or worsening-heart-failure endpoint under trial conditions—not a promise of outcome or access for a particular person.
Cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide and 15.3% with placebo (hazard ratio, 0.62).
The composite result corresponded to a 38% relative reduction and was driven primarily by fewer worsening-heart-failure events. At 52 weeks, the KCCQ clinical summary score improved 6.9 points more with tirzepatide than with placebo. Gastrointestinal adverse events led to trial-drug discontinuation more often with tirzepatide (6.3% versus 1.4%).
Turn the study result into a better program comparison
If this result leads you to compare GLP-1 programs, focus on the details the trial did not evaluate: available plans, clinician oversight, medication status, public price terms, follow-up, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 731 adults with obesity and heart failure with preserved ejection fraction, with an ejection fraction of at least 50%
- Follow-up
- Median follow-up of 104 weeks
- Treatment comparison
- Once-weekly subcutaneous tirzepatide up to 15 mg compared with placebo for at least 52 weeks
- Study design
- International, double-blind, randomized, placebo-controlled outcomes trial
A study result is not a personal treatment plan
This study did not replace heart-failure treatment or determine whether tirzepatide is appropriate for an individual. It did not compare online providers, insurance benefits, pharmacies, or affordability. People with heart failure should review treatment options with their own licensed clinician and care team.
Compare GLP-1 programsWhat this result does not show
- The trial enrolled adults with obesity-related HFpEF and a left-ventricular ejection fraction of at least 50%, not every person who may seek weight management.
- The 38% figure is a relative reduction in a composite endpoint; the cardiovascular-death component alone was imprecisely estimated.
- The study does not compare telehealth providers, compounded products, program cost, coverage, pharmacy access, or individual treatment outcomes.
- The study was funded by Eli Lilly; the peer-reviewed paper and disclosure materials are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine